65,437 trials
Malaria
Primary: Number of Participants With On-Treatments Adverse Events, Serious Adverse Events, and Deaths — 0; 1; 1; 2 Participants
Chronic Hepatitis B
Primary: Incidence of Adverse Events (AEs) — 4; 3; 4; 5 Participants
Anorexia Nervosa
Primary: Recruitment Rate — 2.86 participants recruited per month
Respiratory Syncytial Virus Infections
Primary: Percentage of Maternal Subjects With Any Solicited Administration Site Events — 57.1; 52; 15.2; 1.4 Percentage of maternal subjects
Type 2 Diabetes
Primary: HbA1C — 7.0; 6.7 % of HbA1C
Liver Fibrosis
Primary: Liver Stiffness Measured by MRE — 3.07 kPa
Ketamine · Lactation
Primary: Ketamine Concentration in Breast Milk, up to 12 Hours at 3 Hour Intervals, Following an IM Administration of .5mg/kg Ketamine — 51.2; 22.6; 10.6; 4.5 ng/mL
Part 1 · MELANOMA · SCCHN
Primary: Percentage of Participants With Dose-Limiting Toxicities (DLT) - Part 1 — 0; 0; 0; 0 Percentage of Participants
Alzheimer's Disease
Primary: Mean Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) Total Score at Week 104 (Double-Blind Treatment Phase) — 1.19; 1.41; 1.47 Scores on a…
Suspected or Documented Gram-negative Bacterial Infection
Primary: Imipenem (IMI) Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-∞) — 134.7; 153.2; 219.4; 139.4 μM*hr
Carcinoma, Renal Cell
Primary: Time to Complete Remission of Lesions — 10.9; 15.7 Months
Toxic Shock Syndrome
Primary: Number of Participants (Percentage) With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment — 9; 11; 11; 12 Participants
Depression
Primary: Phase I - Feasibility (Eligibility) — 35; 25 Participants
Hypertension
Primary: Memory Function — 25.5; 24.0; 9.7; 9.0 score on a scale
Alcoholism
Primary: Percentage of Patients With no Heavy Drinking Days After 12 Months — 8; 9 Participants